NNOX — Nano-X Imaging Ltd.

Summary of Nanox (NNOX) Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $4.3 million for Q1 2026, up from $2.8 million year-over-year. This includes $0.9 million from the consolidation of VasoHealthcare IT and $0.5 million from teleradiology services.
• Gross Loss: $2.6 million (GAAP), improved from $3 million in the prior year. Non-GAAP gross loss was $2.2 million compared to $0.4 million.
• Teleradiology Revenue: Increased to $3.1 million from $2.6 million, with a gross profit margin of approximately 24%.
• Net Loss: GAAP net loss of $14.3 million compared to $13.2 million in Q1 2025. Non-GAAP net loss was $11.1 million versus $9.4 million.
• Cash Position: $44.2 million as of March 31, 2026, down from $60 million at the end of 2025. Negative cash flow from operations was $14 million.

2. Strategic Updates and Business Highlights

• Commercial Strategy: Restructured U.S. commercial model focusing on partnerships, leading to multiple agreements with established medical equipment distributors.
• Deployment Focus: Prioritizing installations at high-visibility sites like RadNet, which is now using the Nanox.ARC system in clinical workflows.
• Nano-X Imaging Network: Targeting segments with higher reimbursement rates, such as workers' compensation and concierge medicine.
• AI and Software Solutions: Significant progress in AI partnerships, including a successful pilot with Cedars-Sinai and a transition to revenue-generating deployments in Greece.

3. Forward Guidance and Outlook

• Revenue Guidance: The company has removed its previous 2026 revenue target of $35 million due to longer-than-expected timelines for commercialization. Future guidance will focus on operational and strategic milestones rather than annual revenue figures.
• Expectations for Q2: Management anticipates Q2 will show improvement over Q1, with a ramp-up in deployments and commercial activities expected in Q3 and Q4.

4. Bad News, Challenges, or Points of Concern

• Commercialization Delays: The transition from signed agreements to revenue recognition has been slower than anticipated, influenced by site readiness and regulatory processes.
• Cash Flow Concerns: The company raised doubts about its ability to continue as a going concern, given the negative cash flow and reliance on future funding.
• Operational Restructuring: Ongoing evaluations of South Korean operations may lead to further restructuring or potential wind-downs.

5. Notable Q&A Insights

• Teleradiology Growth: The teleradiology segment has doubled revenues, driven by an increase in customer numbers and higher volumes of MRI and CT scans.
• Deployment Cadence: Approximately 360 units are expected to be deployed over the next two to three years, with 60 units anticipated this year.
• Cost Management: Management expects a reduction in operating expenses due to restructuring efforts and a decrease in headcount in Israel.
• AI Business Breakeven: The AI segment is projected to reach gross profit breakeven potentially by early 2027, slightly delayed from previous estimates.

Overall, while Nanox has made progress in its strategic initiatives and partnerships, it faces significant challenges in commercialization timelines and cash flow management that will require careful navigation moving forward.